ReviewTrends in microbiology2011
Cholesterol catabolism as a therapeutic target in Mycobacterium tuberculosis.
Review in Trends in microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 197 citations in OpenAlex.
- An adenylyl cyclase switch reroutes carbon from growth to virulence lipids inbioRxiv : the preprint server for biology · 2026Article
- Supporting activities of cognate redox partners for sterol-metabolizing P450 enzymes in Mycobacterium neoaurum.The Journal of biological chemistry · 2026Article
- Direct Conversion of Phytosterol to Testosterone via an Integrated Microbial-Enzymatic Strategy.Chemistry & biodiversity · 2026Article
- Article
- Regulatory mechanism of cholesterol transport via LtmA in Mycobacterium smegmatis.Scientific reports · 2026Article
- Article
- Comparative in silico analysis of mce operons across Mycobacteriaceae and Nocardiaceae: Insights into genetic arrangements and regulatory mechanisms.Archives of microbiology · 2025Article
- Mycobacteriumabscessus CYP123 is a steroid hydroxylase with an implication in host infection.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- Fragment-Based Development of Small Molecule Inhibitors TargetingJournal of medicinal chemistry · 2025Article
- Pharmacologic properties and inhibitory activity of 6-azasteroids againstMicrobiology spectrum · 2025Article
- Deciphering drug discovery and microbial pathogenesis research in tuberculosis during the two decades of postgenomic era using entity mining approach.Archives of microbiology · 2023Article
- TargetingRSC medicinal chemistry · 2023Review
- Unravelling and engineering an operon involved in the side-chain degradation of sterols in Mycolicibacterium neoaurum for the production of steroid synthons.Biotechnology for biofuels and bioproducts · 2023Article
- Effects of Bacillus Calmette-Guérin on immunometabolism, microbiome and liver diseasesLiver research (Beijing, China) · 2023Article
- New Insights into the Modification of the Non-Core Metabolic Pathway of Steroids inInternational journal of molecular sciences · 2023Review
- Cyclic AMP-Mediated Inhibition of Cholesterol Catabolism inAntimicrobial agents and chemotherapy · 2023Article
- Clinical strains of Mycobacterium tuberculosis exhibit differential lipid metabolism-associated transcriptome changes in in vitro cholesterol and infection models.Pathogens and disease · 2023Article
- Construction of automated high-throughput screening method for finding efficient 3-ketosteroid 1,2-dehydrogenating strains.Applied microbiology and biotechnology · 2022Article
- Combined enhancement of the propionyl-CoA metabolic pathway for efficient androstenedione production in Mycolicibacterium neoaurum.Microbial cell factories · 2022Article
- The unusual convergence of steroid catabolic pathways inProceedings of the National Academy of Sciences of the United States of America · 2022Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Mycobacterium tuberculosis (Mtb) is an intracellular pathogen that infects 10 million people worldwide and kills 2 million people every year. The uptake and utilization of nutrients by Mtb within the host cell is still poorly understood, although lipids play an important role in Mtb persistence. The recent identification of a large regulon of cholesterol catabolic genes suggests that Mtb can use host sterol for infection and persistence. In this review, we report on recent progress in elucidation of the Mtb cholesterol catabolic reactions and their potential utility as targets for tuberculosis therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.